Literature DB >> 15277429

Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes.

Rui Jiang1, Matthias B Schulze, Tricia Li, Nader Rifai, Meir J Stampfer, Eric B Rimm, Frank B Hu.   

Abstract

OBJECTIVE: To evaluate the role of non-HDL cholesterol and apolipoprotein (apo)B, markers of all potentially atherogenic lipoproteins, as predictors of cardiovascular disease (CVD) in comparison with LDL cholesterol in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: We prospectively followed 746 diabetic men in the Health Professionals' Follow-up Study who were aged 46-81 years and free of CVD or cancer at the time of blood draw in 1993-1994. During 6 years of follow-up, we ascertained 103 incident CVD cases.
RESULTS: We used Cox proportional hazard modeling to estimate the relative risk (RR) of CVD. After adjustment for age, BMI, and other lifestyle risk factors, the multivariate RR of CVD (the highest versus the lowest quartile) was 2.34 (95% CI 1.26-4.32) for non-HDL cholesterol, 2.31 (1.23-4.35) for apoB, and 1.74 (0.99-3.06) for LDL cholesterol. Comparisons of nested models indicate that non-HDL cholesterol, but not apoB, adds significantly to the prediction of CVD risk beyond LDL cholesterol. The area under the receiver operating characteristic curve was 0.685, 0.691, 0.695, and 0.722 for the CVD risk-prediction model with LDL cholesterol, apoB, non-HDL cholesterol, and total cholesterol-to-HDL cholesterol ratio (or the non-HDL-to-HDL cholesterol ratio), respectively.
CONCLUSIONS: Non-HDL cholesterol and apoB are more potent predictors of CVD incidence among diabetic men than LDL cholesterol. Statistically, the ratio of total to HDL cholesterol is the best predictor of CVD in this cohort of diabetic men.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277429     DOI: 10.2337/diacare.27.8.1991

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  53 in total

Review 1.  Cardiovascular risk assessment in type 2 diabetes mellitus.

Authors:  Ebaa Al-Ozairi; R Jan-Willem Middelbeek; Edward S Horton
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

2.  Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.

Authors:  Yutaka Mori; Genshin Kuriyama; Takaaki Tanaka; Naoko Tajima
Journal:  Endocrine       Date:  2009-10-16       Impact factor: 3.633

Review 3.  Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease.

Authors:  William C Cromwell; Thomas A Barringer
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

4.  Non-HDL Cholesterol: A New Endpoint in Cardio-Metabolic Health Monitoring.

Authors:  Ross A Baker; Robert A Forbes
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

5.  Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.

Authors:  M-R Taskinen; P J Barter; C Ehnholm; D R Sullivan; K Mann; J Simes; J D Best; S Hamwood; A C Keech
Journal:  Diabetologia       Date:  2010-06-06       Impact factor: 10.122

6.  Racial disparities in cardiovascular risk factor control in an underinsured population with Type 2 diabetes.

Authors:  Y Wang; P T Katzmarzyk; R Horswell; W Zhao; W Li; J Johnson; D H Ryan; G Hu
Journal:  Diabet Med       Date:  2014-04-30       Impact factor: 4.359

7.  A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease.

Authors:  G Tuncman; E Erbay; X Hom; I De Vivo; H Campos; E B Rimm; G S Hotamisligil
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-25       Impact factor: 11.205

8.  Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites.

Authors:  Seth S Martin; Atif N Qasim; Nehal N Mehta; Megan Wolfe; Karen Terembula; Stanley Schwartz; Nayyar Iqbal; Mark Schutta; Roshanak Bagheri; Muredach P Reilly
Journal:  Diabetes       Date:  2009-06-02       Impact factor: 9.461

9.  Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis.

Authors:  Dimitrios Kirmizis; Evangelia Koutoupa; Apostolos Tsiandoulas; Aphroditi Valtopoulou; Georgios Niavis; Phani Markou; Konstantinos Barboutis
Journal:  Biomark Insights       Date:  2007-02-07

10.  Lipid measures for prediction of incident cardiovascular disease in diabetic and non-diabetic adults: results of the 8.6 years follow-up of a population based cohort study.

Authors:  Maryam Tohidi; Masumeh Hatami; Farzad Hadaegh; Maryam Safarkhani; Hadi Harati; Fereidoun Azizi
Journal:  Lipids Health Dis       Date:  2010-01-23       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.